Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 30 March 2016, 16:41 HKT/SGT
Share:
    

Source: Eisai
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options

TOKYO, Mar 30, 2016 - (JCN Newswire) - Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy").
This submission corresponds to the expiration of the previous shelf registration (period from April 7, 2014 to April 6, 2016) filed on March 28, 2014.

Details
1. Securities Type:
Stock options
2. Issue Period:
Two years from the effective date of the shelf registration of stock options (period from April 7, 2016 to April 6, 2018)
3. Offering Method:
Rights offering to shareholders
4. Issue Amount:
800 million yen (This is the total amount to be paid upon the exercise of all stock options to be issued to subscribers free of charge.)

The Policy serves as an advance warning system for hostile takeovers. It sets forth orderly procedures that must be followed in the event of a large-scale acquisition of the Company's shares so as to ensure that shareholders are provided with sufficient time and information to make appropriate judgments. If and when an acquirer does not follow the prescribed procedures, or the acquisition is inappropriate in that it would undermine the corporate value and common interest of
shareholders, the Company, in accordance with the Policy, issues new stock options to all shareholders, which the acquirer is not entitled to exercise, in order to dilute the voting rights of the acquirer to defend against inappropriate takeover.

The Company initially adopted the Policy at its Board of Directors meeting in February 2006. At its meeting in August 2011, the Board of Directors resolved to continue the Policy as proposed by the Company's Independent Committee of Outside Directors ("ICOD"), which is comprised entirely of independent and neutral outside directors who make up the majority of the Board of Directors. The continuation, amendment or abandonment of the Policy is deliberated each year by the ICOD.

This newly filed shelf registration will provide the Company with the flexibility to issue stock options by offering rights to existing shareholders.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Daily News
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: